The impact of ambrisentan and tadalafil upfront combination therapy on cardiac function in scleroderma associated pulmonary arterial hypertension patients: cardiac magnetic resonance feature tracking study
The aim of this study was to evaluate the effect of upfront combination therapy with ambrisentan and tadalafil on left ventricular (LV) and right ventricular (RV) function in patients with systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH). LV and RV peak longitudinal and circum...
Main Authors: | Takahiro Sato, Bharath Ambale-Venkatesh, Joao A.C. Lima, Stefan L. Zimmerman, Ryan J. Tedford, Tomoki Fujii, Olivia L. Hulme, Erica H. Pullins, Celia P. Corona-Villalobos, Roham T. Zamanian, Omar A. Minai, Reda E. Girgis, Kelly Chin, Rubina Khair, Rachel L. Damico, Todd M. Kolb, Stephen C. Mathai, Paul M. Hassoun |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-02-01
|
Series: | Pulmonary Circulation |
Online Access: | https://doi.org/10.1177/2045893217748307 |
Similar Items
-
Ambrisentan-induced severe asymptomatic thrombocytopenia
by: Dana Kigitovica, et al.
Published: (2020-10-01) -
Cost-utility of ambrisentan and bosentan for pediatric pulmonary arterial hypertension
by: Buendia, JA, et al.
Published: (2023) -
When more is more: the role of additional upfront therapy in pulmonary arterial hypertension
by: Shannon Niedermeyer, et al.
Published: (2023-01-01) -
AMBRISENTAN: THE POSSIBILITY OF THE TREATMENT FOR PULMONARY ARTERIAL HYPERTENSION WITH THE SELECTIVE BLOCKADE OF THE ENDOTHELIN SYSTEM
by: T. V. Martynuk, et al.
Published: (2014-03-01) -
Correction: Periostin overexpression in scleroderma cardiac tissue and its utility as a marker for disease complications
by: Fatima El-Adili, et al.
Published: (2023-01-01)